ChristineM.LovlyMDPhD

PubMed

• 456 citations
  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
  D Westover, J Zugazagoitia, Byoung Chul Cho, Christine M. Lovly, L Paz-Ares
  Annals of Oncology. 2018-01-01
• 549 citations
  Mechanisms of receptor tyrosine kinase activation in cancer.
  Zhenfang Du, Christine M. Lovly
  Molecular Cancer. 2018-02-19
• 29 citations
  Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
  Gregory J Riely, Douglas E Wood, David S Ettinger, Dara L Aisner, Wallace Akerley
  Journal of the National Comprehensive Cancer Network. 2024-05-01

Journal Articles

• Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer  
  Christine M Lovly, Kelli L Boyd, Paula I Gonzalez-Ericsson, Cindy L Lowe, Hunter M Brown, Robert D Hoffman, Brent C Sterling, Meghan E Kapp, Douglas B Johnson, Prasad ..., medRxiv, 5/1/2020
• Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors  
  Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM., Mod Pathol, 5/28/2015
• Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral C...  
  Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM., Cancer Immunol Res, 5/3/2015
• MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking  
  Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M., Clin Cancer Res, 4/15/2015
• Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas  
  Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ., J Thorac Oncol, 3/10/2015
• Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies  
  Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA., Cancer Immunol Res, 3/3/2015
• Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer  
  Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cros..., Mol Cancer Ther, 2/14/2015
• Combating acquired resistance to tyrosine kinase inhibitors in lung cancer  
  Lovly CM, Am Soc Clin Oncol Educ Book, 2015
• Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors  
  Yu HA, Riely GJ, Lovly CM., Clin Cancer Res, 12/1/2014
• NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies  
  Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, R..., J Natl Compr Canc Netw, 11/12/2014
• Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer  
  Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S..., Nat Med, 9/20/2014
• Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions  
  Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM., Cancer Discov, 8/4/2014
• Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation...  
  Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Ke..., Oncologist, 6/19/2014
• Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies  
  Lovly CM, Shaw AT, Clin Cancer Res, 5/1/2014
• Beyond histology: translating tumor genotypes into clinically effective targeted therapies  
  Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W., Clin Cancer Res, 5/1/2014
• Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids  
  Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg..., Nat Commun, 3/27/2014
• A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comp...  
  Lammers PE, Lovly CM, Horn L, J Natl Compr Canc Netw., 1/12/2014
• Characteristics of lung cancers harboring NRAS mutations  
  Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Frank..., Clin Cancer Res., 5/1/2013
• Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer  
  Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-..., Cancer Discov, 4/3/2013
• A 75-year-old man with progressive bronchioalveolar carcinoma  
  Baikadi M, Lovly C, Horn L, Reckamp KL, Noonan K, Laskin J, Morris GJ, Semin Oncol, 2/2013
• Update on HER1-3 in advanced non-small-cell lung cancer  
  Horn L, Lovly C., J Thorac Oncol, 12/2012
• Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC  
  Lovly CM, Horn L., Curr Treat Options Oncol, 12/2012
• Translating genomic information into clinical medicine: lung cancer as a paradigm  
  Levy MA, Lovly CM, Pao W., Genome Res., 11/2012
• Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants  
  Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK., Clin Cancer Res, 9/1/2012
• ROS1 rearrangements define a unique molecular class of lung cancers  
  Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW,..., J Clin Oncol, 3/10/2012
• Join now to see all